Literature DB >> 21159395

Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).

Seong-Jang Kim1, Yong-Ki Kim, In Joo Kim, Young Dae Kim, Min Ki Lee.   

Abstract

OBJECTIVE: The aim of the current study was to investigate the prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) NSCLC.
METHODS: A retrospective review identified 66 patients with surgically resected early (stage I & II) NSCLC who received dual time point F-18 FDG PET/CT at diagnosis of cancer. Survival analysis was conducted using Kaplan-Meier analysis, and survival curves stratified by age, sex, mediastinal lymph node involvement, TNM staging, SUV(maxE), SUV(maxD), and %ΔSUV(max) were generated for estimation of overall survival and disease-free survival (DFS). Independent predictive factors for survival were determined using Cox proportional hazard model.
RESULTS: The overall survival and DFS were better in patients with tumor SUV(maxE)≤5.75 than the patients with tumor SUV(maxE)≥5.75. Seventeen patients (18.2%) with a tumor SUV(maxD)≥6.8 and 4 of 33 patients with tumor SUV(maxD)≤6.8 recurred during follow-up period. The median disease-free survival of the patients with tumor SUV(maxD)≥6.8 was 31.7 months and was significantly worse than the patients with tumor SUV(maxD)≤6.8 (Log rank test, Χ(2)=10.45, p=0.0012). The %ΔSUV(max) did not have prognostic values for overall survival and disease-free survival. The SUV(maxE) and SUV(maxD) were the potent predictors for overall survival. Also, the potent predictor of DFS was the SUV(maxE).
CONCLUSION: In conclusion, %ΔSUV(max) measured by dual time point F-18 FDG PET/CT might not have a prognostic value for overall survival and DFS in surgically resected early stage (stage I & II) NSCLC. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159395     DOI: 10.1016/j.radonc.2010.11.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  The Clinical Role of Dual-Time-Point (18)F-FDG PET/CT in Differential Diagnosis of the Thyroid Incidentaloma.

Authors:  Sinae Lee; Taegyu Park; Soyeon Park; Kisoo Pahk; Seunghong Rhee; Jaehyuk Cho; Eugene Jeong; Sungeun Kim; Jae Gol Choe
Journal:  Nucl Med Mol Imaging       Date:  2013-12-06

2.  Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer.

Authors:  Wouter van Elmpt; Michel Ollers; Anne-Marie C Dingemans; Philippe Lambin; Dirk De Ruysscher
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

3.  The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer.

Authors:  Helen H W Chen; Bi-Fang Lee; Wu-Chou Su; Yu-Hsuan Lai; Hung-Yu Chen; How-Ran Guo; Wei-Jen Yao; Nan-Tsing Chiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-07       Impact factor: 9.236

4.  Prognostic Value of Dual-Time-Point [18F]FDG PET/CT for Predicting Distant Metastasis after Treatment in Patients with Non-Small Cell Lung Cancer.

Authors:  Sang Mi Lee; Jeong Won Lee; Ji-Hyun Lee; In Young Jo; Su Jin Jang
Journal:  J Pers Med       Date:  2022-04-07

Review 5.  When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Authors:  Gang Cheng; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

Review 6.  Positron emission tomography-computed tomography in the management of lung cancer: An update.

Authors:  Punit Sharma; Harmandeep Singh; Sandip Basu; Rakesh Kumar
Journal:  South Asian J Cancer       Date:  2013-07

7.  Diagnostic Accuracy of Dual-Time-Point Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Verification Local Recurrence in Pancreatic Cancer Patients.

Authors:  Esraa El-Kholy; Lobna Khaled
Journal:  Indian J Nucl Med       Date:  2019 Oct-Dec

8.  Different Prognostic Values of Dual-Time-Point FDG PET/CT Imaging Features According to Treatment Modality in Patients with Non-Small Cell Lung Cancer.

Authors:  Su Jin Jang; Jeong Won Lee; Ji-Hyun Lee; In Young Jo; Sang Mi Lee
Journal:  Tomography       Date:  2022-04-08

9.  Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.

Authors:  Feng Jin; Hui Zhu; Zheng Fu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-05-19       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.